发布求助
文献互助 智能选刊 最新文献

Therapeutic delivery最新文献

筛选
英文 中文
Potential role of herbal nanoformulations for skin disorders: a review. 草药纳米制剂对皮肤疾病的潜在作用：综述。
IF 4.2
Therapeutic delivery Pub Date : 2023-08-01 Epub Date: 2023-09-12 DOI: 10.4155/tde-2023-0024
Sahil Arora, Charul Rathore
{"title":"Potential role of herbal nanoformulations for skin disorders: a review.","authors":"Sahil Arora,&nbsp;Charul Rathore","doi":"10.4155/tde-2023-0024","DOIUrl":"10.4155/tde-2023-0024","url":null,"abstract":"<p><p><b>Aim:</b> In the recent advanced study, the popularity of herbal nano-formulation has gained around the whole world. As we know the reason behind it is that herbal products have comparatively lesser side effects than other synthetic products. <b>Significance:</b> These natural plant extracts have wide medicinal importance as they increase the overall bioavailability of products toward tissues. <b>Key findings:</b> This review provides the use of different herbal nano-formulations, their safety considerations, and the challenges being faced. It also highlights the various Clinical Trials and Patents that are published for skin disorders. <b>Conclusion:</b> The present review describes how the rise of herbal products has made wider interest in transdermal formulations and improve the overall productivity by preventing various skin disorders.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 8","pages":"511-525"},"PeriodicalIF":4.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10294472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry update, June 2023. 行业更新，2023年6月。
IF 4.2
Therapeutic delivery Pub Date : 2023-08-01 DOI: 10.4155/tde-2023-0068
Elaine Harris
{"title":"Industry update, June 2023.","authors":"Elaine Harris","doi":"10.4155/tde-2023-0068","DOIUrl":"https://doi.org/10.4155/tde-2023-0068","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 8","pages":"477-484"},"PeriodicalIF":4.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10586114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhaled nintentanib, pirfenidone and macitentan for pulmonary fibrosis: a laboratory experiment. 吸入宁替尼、吡非尼酮和马西坦治疗肺纤维化：一项实验室实验。
IF 4.2
Therapeutic delivery Pub Date : 2023-08-01 Epub Date: 2023-08-16 DOI: 10.4155/tde-2023-0045
Paul Zarogoulidis, Dimitris Petridis, Haidong Huang, Chong Bai, Panagoula Oikonomou, Christina Nikolaou, Dimitris Matthaios, Eleni-Isidora Perdikouri, Vasilis Papadopoulos, Savvas Petanidis, Christoforos Kosmidis, Charalampos Charalampidis, Wolfgang Hohenforst-Schmidt, Nikos Kougkas, Chrysanthi Sardeli
{"title":"Inhaled nintentanib, pirfenidone and macitentan for pulmonary fibrosis: a laboratory experiment.","authors":"Paul Zarogoulidis,&nbsp;Dimitris Petridis,&nbsp;Haidong Huang,&nbsp;Chong Bai,&nbsp;Panagoula Oikonomou,&nbsp;Christina Nikolaou,&nbsp;Dimitris Matthaios,&nbsp;Eleni-Isidora Perdikouri,&nbsp;Vasilis Papadopoulos,&nbsp;Savvas Petanidis,&nbsp;Christoforos Kosmidis,&nbsp;Charalampos Charalampidis,&nbsp;Wolfgang Hohenforst-Schmidt,&nbsp;Nikos Kougkas,&nbsp;Chrysanthi Sardeli","doi":"10.4155/tde-2023-0045","DOIUrl":"10.4155/tde-2023-0045","url":null,"abstract":"<p><p><b>Aim:</b> Idiopathic pulmonary fibrosis is a rare disease with few efficient drugs in the market. The consequences of this disease are mainly respiratory failure and pulmonary hypertension. <b>Materials & methods:</b> In our experiment we used the drugs pirfenidone, nintetanib and macitentan. We performed nebulization experiments with three jet nebulizers and three ultrasound nebulizers with different combinations of residual cup designs, and residual cup loadings in order to identify which combination produces droplets of less than 5 μm in mass median aerodynamic diameter. <b>Results:</b> Pirfenidone versus nintetanib had smaller droplet size formation at both inhaled technologies (1.37 < 2.23 and 1.92 < 3.11, jet and ultrasound respectively). <b>Discussion:</b> Pirfenidone and nintetanib can be administered as aerosol in any type of nebulization system.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 8","pages":"491-498"},"PeriodicalIF":4.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10603729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can Amphotericin B-mediated effects be limited using intranasal versus intravenous route? 两性霉素B介导的作用是否可以通过鼻内和静脉途径受到限制？
IF 4.2
Therapeutic delivery Pub Date : 2023-08-01 Epub Date: 2023-09-11 DOI: 10.4155/tde-2023-0032
Ruqaiyyah Siddiqui, Timothy Yu Yee Ong, Sutherland Maciver, Naveed Ahmed Khan
{"title":"Can Amphotericin B-mediated effects be limited using intranasal versus intravenous route?","authors":"Ruqaiyyah Siddiqui,&nbsp;Timothy Yu Yee Ong,&nbsp;Sutherland Maciver,&nbsp;Naveed Ahmed Khan","doi":"10.4155/tde-2023-0032","DOIUrl":"10.4155/tde-2023-0032","url":null,"abstract":"<p><p><b>Aim:</b> CNS infections due to parasites often prove fatal. In part, this is due to inefficacy of drugs to cross the blood-brain barrier. <b>Methods:</b> Here, we tested intranasal and intravenous route and compared adverse effects of Amphotericin B administration, through blood biochemistry, liver, kidney and brain histopathological evidence of toxicities <i>in vivo</i> post-administration. <b>Results:</b> It was observed that intranasal route limits the adverse side effects of Amphotericin B, in contrast to intravenous route. <b>Conclusion:</b> As parasites such as <i>Naegleria fowleri</i> exhibit unequivocal affinity toward the olfactory bulb and frontal lobe in the central nervous system, intranasal administration would directly reach amoebae bypassing the blood-brain barrier selectivity and achieve the minimum inhibitory concentration at the target site.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 8","pages":"485-490"},"PeriodicalIF":4.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10239587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ex vivo analysis of ketotifen content in an antihistamine-eluting contact lens worn up to 5 hours. 佩戴5小时的抗组胺洗脱隐形眼镜中酮替芬含量的体外分析。
IF 4.2
Therapeutic delivery Pub Date : 2023-07-01 DOI: 10.4155/tde-2023-0029
Brian Pall, Shivkumar Mahadevan, Azaam Alli, Frank Yi, Paul Gomes
{"title":"<i>Ex vivo</i> analysis of ketotifen content in an antihistamine-eluting contact lens worn up to 5 hours.","authors":"Brian Pall,&nbsp;Shivkumar Mahadevan,&nbsp;Azaam Alli,&nbsp;Frank Yi,&nbsp;Paul Gomes","doi":"10.4155/tde-2023-0029","DOIUrl":"https://doi.org/10.4155/tde-2023-0029","url":null,"abstract":"<p><p><b>Aim:</b> This study characterized <i>ex vivo</i> release of ketotifen from etafilcon A contact lenses worn over 5 h. <b>Materials & methods:</b> 14 participants, 21 to 59 years, wore lenses with 19 μg ketotifen over 8 visits, for 1 min to 5 h. Residual ketotifen was measured using high-performance liquid chromatography (HPLC) compared with unworn lenses from the same lots to determine percent ketotifen remaining. <b>Results:</b> Residual ketotifen ranged from 16.19 μg ± 0.44 (84.1%) [1 minute] to 0.20 μg ± 0.07 (1.1%) [5 h]. No adverse events or clinically significant biomicroscopy changes were observed. <b>Conclusion:</b> The ketotifen-releasing etafilcon A lenses were well-tolerated with an acceptable safety profile in the population studied. The release of ketotifen from study lenses over 5 h was consistent with a diffusion-controlled system.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 7","pages":"407-417"},"PeriodicalIF":4.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10189953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A short appraisal of polylactic-co-glycolic acid based polymer nanotechnology for colon cancer: recent advances and literature evidences. 以聚乳酸-羟基乙酸为基础的高分子纳米技术治疗结肠癌:最新进展和文献证据。
IF 4.2
Therapeutic delivery Pub Date : 2023-07-01 DOI: 10.4155/tde-2023-0027
Abhinav Vashishat, Amrinder Singh, Balak Das Kurmi, Ghanshyam Das Gupta, Dilpreet Singh
{"title":"A short appraisal of polylactic-co-glycolic acid based polymer nanotechnology for colon cancer: recent advances and literature evidences.","authors":"Abhinav Vashishat,&nbsp;Amrinder Singh,&nbsp;Balak Das Kurmi,&nbsp;Ghanshyam Das Gupta,&nbsp;Dilpreet Singh","doi":"10.4155/tde-2023-0027","DOIUrl":"https://doi.org/10.4155/tde-2023-0027","url":null,"abstract":"<p><p>The currently available formulations provided non-targeted treatment of colon cancer, the deadliest cancer variant. Due to biopharmaceutical hindrances, the majority of the drugs are unable to reach the target site. Polylactic-co-glycolic acid (PLGA) is one of the versatile polymers in cancer treatment, diagnostics and theranostics. The unique mechanism of surface modifications in PLGA properties in colon cancer has been a keen interest to be used in different nanoparticles for improving biopharmaceutical attributes. The ongoing use of these smart nano-carriers has allowed targeted delivery of several active components on a wide scale. The main goal of this review is to compile information on PLGA-based nanocarriers which possess several desirable properties for drug delivery applications, including biocompatibility, biodegradability and tunable drug-release kinetics.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 7","pages":"459-472"},"PeriodicalIF":4.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10188585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comprehensive review on pharmaceutical excipients. 药用辅料综述。
IF 4.2
Therapeutic delivery Pub Date : 2023-07-01 DOI: 10.4155/tde-2023-0026
Rachana D Pockle, Rajashree S Masareddy, Archana S Patil, Pragati D Patil
{"title":"A comprehensive review on pharmaceutical excipients.","authors":"Rachana D Pockle,&nbsp;Rajashree S Masareddy,&nbsp;Archana S Patil,&nbsp;Pragati D Patil","doi":"10.4155/tde-2023-0026","DOIUrl":"https://doi.org/10.4155/tde-2023-0026","url":null,"abstract":"<p><p>The effectiveness of pharmaceutical drugs depends not only on their active components and manufacturing processes, but also on the role played by pharmaceutical excipients. The traditional definition of excipients as inactive and cost-effective substances has evolved significantly. They are now recognized as essential elements of drug formulations, constituting 80-90% of the final product. The rapid advancements in delivery systems, along with scientific, regulatory, financial and technological developments in biopharmaceutics, have generated renewed interest in the use and functionality of excipients, especially in solid dosage forms. This review focuses on the categorization of excipients according to the International Pharmaceutical Excipient Council (IPEC) and the establishment of guidelines for evaluating the safety of a new proposed excipient.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 7","pages":"443-458"},"PeriodicalIF":4.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10186658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Cell-penetrating peptides are widely used molecular transporter for peptide delivery in cancer: recent advancements. 细胞穿透肽是一种广泛应用于肿瘤肽传递的分子转运体。
IF 4.2
Therapeutic delivery Pub Date : 2023-07-01 DOI: 10.4155/tde-2023-0050
Dilpreet Singh
{"title":"Cell-penetrating peptides are widely used molecular transporter for peptide delivery in cancer: recent advancements.","authors":"Dilpreet Singh","doi":"10.4155/tde-2023-0050","DOIUrl":"https://doi.org/10.4155/tde-2023-0050","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 7","pages":"401-405"},"PeriodicalIF":4.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10189934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ophthalmic nano-bioconjugates: critical challenges and technological advances. 眼科纳米生物偶联物:关键挑战和技术进步。
IF 4.2
Therapeutic delivery Pub Date : 2023-07-01 DOI: 10.4155/tde-2023-0031
Sachin Nashik Sanap, Amol Chhatrapati Bisen, Sristi Agrawal, Ashwini Kedar, Rabi Sankar Bhatta
{"title":"Ophthalmic nano-bioconjugates: critical challenges and technological advances.","authors":"Sachin Nashik Sanap,&nbsp;Amol Chhatrapati Bisen,&nbsp;Sristi Agrawal,&nbsp;Ashwini Kedar,&nbsp;Rabi Sankar Bhatta","doi":"10.4155/tde-2023-0031","DOIUrl":"https://doi.org/10.4155/tde-2023-0031","url":null,"abstract":"<p><p>Ophthalmic disease can cause permanent loss of vision and blindness. Easy-to-administer topical and systemic treatments are preferred for treating sight-threatening disorders. Typical ocular anatomy makes topical and systemic ophthalmic drug delivery challenging. Various novel nano-drug delivery approaches are developed to attain the desired bioavailability in the eye by increasing residence time and improved permeability across the cornea. The review focuses on novel methods that are biocompatible, safe and highly therapeutic. Novelty in nanocarrier design and modification can overcome their drawbacks and make them potential drug carriers for eye disorders in both the anterior and posterior eye segments. This review briefly discussed technologies, patented developments, and clinical trial data to support nanocarriers' use in ocular drug delivery.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 7","pages":"419-441"},"PeriodicalIF":4.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10189933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancements in therapeutic approaches for malignant peripheral nerve sheath tumor. 恶性周围神经鞘肿瘤治疗方法的研究进展。
IF 4.2
Therapeutic delivery Pub Date : 2023-06-01 DOI: 10.4155/tde-2023-0014
Elena Millesi, Julian S Rechberger, Huan Wang, Samir Mardini, Robert J Spinner, David J Daniels
{"title":"Advancements in therapeutic approaches for malignant peripheral nerve sheath tumor.","authors":"Elena Millesi,&nbsp;Julian S Rechberger,&nbsp;Huan Wang,&nbsp;Samir Mardini,&nbsp;Robert J Spinner,&nbsp;David J Daniels","doi":"10.4155/tde-2023-0014","DOIUrl":"https://doi.org/10.4155/tde-2023-0014","url":null,"abstract":"<p><p>Tweetable abstract Emerging targeted therapies offer hope for malignant peripheral nerve sheath tumor. Innovative drug delivery enhances potential treatments. #MPNST #TargetedTherapies #TherapeuticDelivery.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 6","pages":"385-389"},"PeriodicalIF":4.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10186657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信